# Nuclide record multiple-endocrine-neoplasia (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/multiple-endocrine-neoplasia/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "multiple-endocrine-neoplasia" ;
  schema:name "Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)"@en ;
  schema:alternateName "MEN1"@en, "MEN2A"@en, "MEN2B"@en, "MEN4"@en, "Wermer syndrome"@en, "Sipple syndrome"@en ;
  schema:description "The MEN syndromes are inherited faults in a single gene that cause tumours in several hormone glands over a lifetime. Because the gene can be found in childhood, at-risk relatives can be tested, watched and in MEN2 have the thyroid removed before cancer develops; and for MEN2 thyroid cancer that does spread there is now a precise pill, selpercatinib, that blocks the faulty RET protein."@en ;
  schema:url <https://nuclide.cc/indications/multiple-endocrine-neoplasia/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia> ;
  schema:citation <https://www.cancer.gov/types/multiple-endocrine-neoplasia>, <https://doi.org/10.1089/thy.2014.0335>, <https://doi.org/10.1210/jc.2012-1230>, <https://doi.org/10.1056/NEJMoa2309719> ;
  nuclide:tag "nci-coverage", "rare", "endocrine", "hereditary" ;
  nuclide:related <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/thyroid/>, <https://nuclide.cc/indications/pheochromocytoma-paraganglioma/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:technologies <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/sstr-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:companies <https://nuclide.cc/companies/eli-lilly/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/everolimus/> ;
  nuclide:standardOfCare <https://nuclide.cc/indications/thyroid/>, <https://nuclide.cc/indications/pheochromocytoma-paraganglioma/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/indications/neuroendocrine/> .